Bill · S. 2027· Senate(119-S-2027)
Prescription Information Modernization Act of 2025
- Introduced
- 6/11/2025
- Last activity
- 6/11/2025 — Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Sponsored by
- Markwayne Mullin
- Cosponsors
- - 0 - 1
- Introduced
- In Committee
What this bill would do
This bill, known as the "Prescription Information Modernization Act of 2025," aims to allow the digital communication of FDA-approved prescribing information for drugs and biological products. It would amend the Federal Food, Drug, and Cosmetic Act to permit required information to be provided solely through electronic means. Under this Act, manufacturers must still allow prescribers and dispensers to opt for paper versions or request them as needed at no extra cost. The Secretary of Health and Human Services is tasked with issuing final regulations and minimizing economic impacts on healthcare providers. Additionally, a public workshop will be held to discuss the optimization of prescribing information accessibility and usability.
Who it would affect, and how
Potential Positive Impacts for People
-
Digital Accessibility: Manufacturers may make required prescribing information available solely by electronic means, which could modernize how information is accessed (Section 2(a)).
-
Flexibility for Healthcare Providers: Prescribers and dispensers are given the opportunity to elect to continue receiving information in paper form, ensuring they are not forced to go digital if they prefer otherwise (Section 2(a)).
-
No-Cost Information Requests: If a provider requests paper labeling on an as-needed basis, the manufacturer must promptly provide it without any additional cost (Section 2(a)).
-
Stakeholder Engagement: The Secretary of Food and Drugs must hold a public workshop to discuss ways to optimize the format, accessibility, and usability of prescribing information (Section 2(c)).
Potential Negative Impacts for People
- Economic Burden on Healthcare Providers: There is a recognition that new regulations could have adverse economic impacts on prescribers and dispensers, requiring the Secretary to design regulations specifically to minimize these effects (Section 2(b)(2)).
Groups and Interests Ranking
Every group the model scored this bill for, from -10 to +10. Hover a score for the reason it gave.
No significant interests or groups are affected by this bill.
- 6/11/2025
- Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 1 Cosponsor added.
- Introduced in Senate
2 bills Congress.gov lists as related to this one — companions in the other chamber, earlier versions, and bills this one absorbed or was folded into.
Cory BookerDemocrat · New Jersey